EMA Authorised: Esperoct (turoctocog alfa pegol) — Novo Nordisk A/S

View source ↗

Summary

EMA authorised Esperoct (turoctocog alfa pegol) from Novo Nordisk A/S for the treatment of hemophilia A. The decision date was 21 October 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Esperoct (turoctocog alfa pegol)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Novo Nordisk A/S. Decision date: 21/10/2024